Sarepta Therapeutics (NASDAQ:SRPT) Trading 8.8% Higher – Still a Buy?

Posted by Brian Himes on Jun 17th, 2026

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) traded up 8.8% during mid-day trading on Wednesday . The company traded as high as $17.35 and last traded at $17.1680. 568,266 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 2,885,650 shares. The stock had previously closed at $15.78.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Mizuho increased their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, June 11th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Finally, Oppenheimer restated an “outperform” rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and an average price target of $24.77.

View Our Latest Report on SRPT

Sarepta Therapeutics Price Performance

The business has a 50-day moving average price of $18.93 and a 200 day moving average price of $19.69. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -18.49, a P/E/G ratio of 0.17 and a beta of 0.21. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. During the same quarter in the prior year, the firm earned ($3.42) EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SRPT. AQR Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 214.2% during the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 3,671 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at $224,000. Guggenheim Capital LLC lifted its position in shares of Sarepta Therapeutics by 33.5% during the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock valued at $783,000 after acquiring an additional 11,497 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Sarepta Therapeutics by 59.2% during the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock valued at $10,731,000 after acquiring an additional 233,391 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in Sarepta Therapeutics by 7.1% during the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock valued at $1,972,000 after purchasing an additional 7,665 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.